Fol. Biol. 2021, 67, 1-9

https://doi.org/10.14712/fb2021067010001

Questioning How to Define the “Ultra-High-Risk” Subgroup of Neuroblastoma Patients

A. B. Demir1,2, Safiye Aktas2, Z. Altun2, P. Ercetin2, T. C. Aktas2, N. Olgun3

1Department of Basic Medical Sciences, Faculty of Medicine, Izmir University of Economics, Izmir, Turkey
2Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey
3Department of Clinical Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey

Received April 2020
Accepted November 2020

References

1. Abel, F., Ejeskar, K., Kogner, P., Martinson T. (1999) Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br. J. Cancer 8, 1402-1409. <https://doi.org/10.1038/sj.bjc.6692231>
2. Azarova, A. M., Gautam, G., George, R. E. (2011) Emerging importance of ALK in neuroblastoma. Semin. Cancer Biol. 21, 267-275. <https://doi.org/10.1016/j.semcancer.2011.09.005>
3. Brodeur, G. M., Seeger, R. C., Barrett, A., Berthold, F., Castleberry, R. P., D’Angio, G., De Bernardi, B., Evans, A. E., Favrot, M., Freeman, A. I. (1988) International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J. Clin. Oncol. 6, 1874-1881. <https://doi.org/10.1200/JCO.1988.6.12.1874>
4. Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V., Castleberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., Hedborg, F. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11, 1466-1477. <https://doi.org/10.1200/JCO.1993.11.8.1466>
5. Caren, H., Erichsen, J., Olsson, L., Enerback, C., Sjoberg, R. M., Abrahamsson, J., Kogner, P., Martinsson, T. (2008) High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics 9, 353. <https://doi.org/10.1186/1471-2164-9-353>
6. Caron, H. (1995) Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med. Pediatr. Oncol. 24, 215-221. <https://doi.org/10.1002/mpo.2950240402>
7. Cheung, N. K., Zhang, J, Lu, C., Parker, M., Bahrami, A., Tickoo, S. K., Heguy, A., Pappo, A. S., Federico, S., Dalton, J., Cheung, I. Y., Ding, L., Fulton, R., Wang, J., Chen, X., Becksfort, J., Wu, J., Billups, C. A., Ellison, D., Mardis, E. R., Wilson, R. K., Downing, J. R., Dyer, M. A. (2012) Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307, 1062-1071. <https://doi.org/10.1001/jama.2012.228>
8. Cohn, S. L., Pearson, A. D., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Lehara, T., Machin, D., Mosseri, V., Simon, T., Garaventa, A., Caste, V., Matthay, K. K. (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 27, 289-297. <https://doi.org/10.1200/JCO.2008.16.6785>
9. Firlej, V., Ladam, F., Brysbaert, G., Dumont, P., Fuks, F., de Launoit, Y., Benecke, A., Chotteau-Lelievre, A. (2008) Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription. J. Cell Sci. 121, 3393-3402. <https://doi.org/10.1242/jcs.027201>
10. Fujita, T., Igarashi, J., Okawa, E.R., Gotoh, T., Manne, J., Kolla, V., Kim, J., Zhao, H., Pawel, B. R., London, W. B., Maris, J. M., White, P. S., Brodeur, G. M. (2008) CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl. Cancer Inst. 100, 940-949. <https://doi.org/10.1093/jnci/djn176>
11. George, R. E., Sanda, T., Hanna, M., Frohling, S., Luther, W. 2nd, Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., Xue, L., Zozulya, S., Gregor, V. E., Webb, T. R., Gray, N. S., Gilliland, D. G., Diller, L., Greulich, H., Morris, S. W., Meyerson, M., Look, A. T. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978. <https://doi.org/10.1038/nature07397>
12. Gilbert, F. Feder, M., Balaban, G., Brangman, D., Lurie, D. K., Podolsky, R., Rinaldt, V., Vinikoor, N., Weisband, J. (1984) Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 44, 5444-5449.
13. Guo, C., White, P. S., Weiss, M. J., Hogarty, M. D., Thompson, P. M., Stram, D. O, Gerbing, R., Matthay, K. K., Seeger, R. C., Brodeur, G. M., Maris, J. M. (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18, 4948-4957. <https://doi.org/10.1038/sj.onc.1202887>
14. Hamidian, A., von Stedingk, K., Munksgaard Thoren, M., Mohlin, S., Pahlman, S. (2015) Differential regulation of HIF-1 α and HIF-2α in neuroblastoma: estrogen-related receptor α (ERRα) regulates HIF2A transcription and correlates to poor outcome. Biochem. Biophys. Res. Commun. 461, 560-567. <https://doi.org/10.1016/j.bbrc.2015.04.083>
15. Helczynska, K., Larsson, A. M., Holmquist Mengelbier, L., Bridges, E., Fredlund, E., Borgquist, S., Landberg, G., Pahlman, S., Jirstrom, K. (2008) Hypoxia-inducible factor- 2α correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 68, 9212-9220. <https://doi.org/10.1158/0008-5472.CAN-08-1135>
16. Hertwig, F., Peifer, M., Fischer, M. (2016) Telomere maintenance is pivotal for high-risk neuroblastoma. Cell Cycle 15, 311-312. <https://doi.org/10.1080/15384101.2015.1125243>
17. Jedlicka, P., Gutierrez-Hartmann, A. (2008) Ets transcription factors in intestinal morphogenesis, homeostasis and disease. Histol. Histopathol. 23, 1417-1424.
18. Killela, P. J., Reitman, Z. J., Jiao, Y., İao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A. Jr., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., Grollman, A. P., He, T. C., He, Y., Hruban, R. H., Jallo, G. I., Mandahl, N., Meeker, A. K., Mertens, F., Netto, G. J., Rasheed, B. A., Riggins, G. J., Rosenquist, T. A., Schiffman, M, Shih, I. M., Theodorescu, D., Torbenson, M. S., Velculescu, V. E., Wang, T. L., Wentzensen, N., Wood, L. D., Zhang, M., McLendon, R. E., Bigner, D. D., Kinzler, K, W., Vogelstein, B., Papadopoulos, N., Yan, H. (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. USA 110, 6021-6026. <https://doi.org/10.1073/pnas.1303607110>
19. Mazzocco, K., Defferrari, R., Sementa, A. R., Garaventa A, Longo L, De Mariano M, Esposito M. R., Negri, F., Ircolò, D., Viscardi, E., Luksch, R., D’Angelo, P., Prete, A., Castellano, A., Massirio, P., Erminio, G., Gigliotti, A. R., Tonini, G. P., Conte, M. (2015) Genetic abnormalities in adolescents and young adults with neuroblastoma: a report from the Italian Neuroblastoma group. Pediatr. Blood Cancer 62, 1725-1732. <https://doi.org/10.1002/pbc.25552>
20. Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., Ebus, M. E., Haneveld, F., Lakeman, A., Schild, L., Molenaar, P., Stroeken, P., van Noesel, M. M., Ora, I., Santo, E. E., Caron, H. N., Westerhout, E. M., Versteeg, R. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589-593. <https://doi.org/10.1038/nature10910>
21. Monge, M., Colas, E., Doll, A., Gonzalez, M., Gil-Moreno, A., Planaguma, J., Quiles, M., Arbos, M. A., Garcia, A., Castellvi, J., Llaurado, M., Rigau, M., Alazzouzi, H., Xercavins, J., Alameda, F., Reventos, J., Abal, M. (2007) ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res. 67, 6753-6759. <https://doi.org/10.1158/0008-5472.CAN-06-4487>
22. Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Mattha,y K. K., Nuchtern, J. G., von Schweinitz, D., Simon, T., Cohn, S. L., Pearson, A. D.; INRG Task Force. (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J. Clin. Oncol. 27, 298-303. <https://doi.org/10.1200/JCO.2008.16.6876>
23. Nicolai, S., Pieraccioli, M., Peschiaroli, A., Melino, G., Raschellà, G. (2015) Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis. 6, e2010. <https://doi.org/10.1038/cddis.2015.354>
24. Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Krämer, A., Roncaioli, J. L., Sand, F., Heuckmann, J. M., Ikram, F., Schmidt, R., Ackermann, S., Engesser, A., Kahlert, Y., Vogel, W., Altmüller, J., Nürnberg, P., Thierry-Mieg, J., Thierry-Mieg, D., Mariappan, A., Heynck, S., Mariotti, E., Henrich, K. O., Gloeckner, C., Bosco, G., Leuschner, I., Schweiger, M. R., Savelyeva, L., Watkins, S. C., Shao, C., Bell, E., Höfer, T., Achter, V., Lang, U., Theissen, J., Volland, R., Saadati, M., Eggert, A., de Wilde, B., Berthold, F., Peng, Z., Zhao, C., Shi, L., Ortmann, M., Büttner, R., Perner, S., Hero, B., Schramm, A., Schulte, J. H., Herrmann, C., O’Sullivan, R. J, Westermann, F., Thomas, R. K, Fischer, M. (2015) Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700-704. <https://doi.org/10.1038/nature14980>
25. Ratner, N., Brodeur, G.M., Dale, R.C., Schor, N. F. (2016) The “neuro” of neuroblastoma: neuroblastoma as a neurodevelopmental disorder. Ann. Neurol. 80, 13-23. <https://doi.org/10.1002/ana.24659>
26. Schonherr, C., Ruuth, K., Kamaraj, S., Wang, C. L., Yang, H. L., Combaret, V., Djos, A., Martinsson, T., Christensen, J. G., Palmer, R. H., Hallberg, B. (2012) Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 31, 5193-5200. <https://doi.org/10.1038/onc.2012.12>
27. Shimada. H., Chatten. J., Newton. W.A., Sachs, N., Hamoudi, A. B., Chiba, T., MArsden, H. B., Misugi, K. (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an agelinked classification of neuroblastomas. J. Natl. Cancer Inst. 73, 405-416. <https://doi.org/10.1093/jnci/73.2.405>
28. Uruga, H., Mino-Kenudson, M. (2018) Alk (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. Pharmgenomics Pers. Med. 11, 147-155.
29. Valentijn, L. J., Koster, J., Zwijnenburg, D. A., Hasselt, N. E., van Sluis, P., Volckmann, R., van Noesel, M. M., George, R. E., Tytgat, G. A., Molenaar, J. J., Versteeg, R. (2015) TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat. Genet. 47, 1411-1414. <https://doi.org/10.1038/ng.3438>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Archive